

Datasheet: HCA329

Description:	HUMAN ANTI IPILIMUMAB
Specificity:	IPILIMUMAB
Other names:	Yervoy
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD34429ia
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.

Preparation

Purified IgG prepared by affinity chromatography on Protein A

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.01% Thiomersal

Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml

Immunogen

Ipilimumab

Specificity

Human Anti-Ipilimumab Antibody, clone AbD34429ia is a paratope specific, inhibitory anti-idiotypic antibody that specifically recognizes the monoclonal antibody ipilimumab. It does not recognize free human CTLA-4 (cytotoxic T-lymphocyte antigen-4) or ipilimumab in complex with CTLA-4.

Clone AbD34429ia is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or reference standard in an anti-drug antibody (ADA) assay. This antibody has a monovalent intrinsic affinity of 1 nM, and is one of three antibodies with

different affinities offered for ADA assays. Antibody [HCA327](#) has affinity 16 nM and [HCA328](#) has affinity 0.3 nM.

Ipilimumab (Yervoy) is a human IgG1/kappa antibody developed from a transgenic mouse. It has been approved by the FDA for the treatment of metastatic melanoma, renal cell carcinoma, and in combination with nivolumab for the treatment of previously treated microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) metastatic colorectal cancer. Ipilimumab activates the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. The action of cytotoxic T lymphocytes (CTLs) to recognize and destroy cancer cells is subject to an inhibitory mechanism that interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to function.

[View a summary of all anti-ipilimumab antibodies](#)

Affinity	The monovalent intrinsic affinity of AbD34429ia was measured as $K_D = 1$ nM by real time, label free molecular interaction analysis on immobilized ipilimumab.
ELISA	Clone AbD34429ia can be used in an indirect ELISA or as a detection antibody for ipilimumab in a bridging ELISA together with HCA330 as the capture reagent. It can also be used as a surrogate positive control or calibrator in an anti-drug antibody assay. Protocol: Protocol:
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Yervoy is a trademark of Bristol-Myers Squibb Company.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Useful Reagents

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)
[HISPEC ASSAY DILUENT \(BUF049A\)](#)
[HUMAN ANTI IPILIMUMAB \(HCA327\)](#)
[HUMAN ANTI IPILIMUMAB \(HCA328\)](#)
[HUMAN ANTI IPILIMUMAB \(HCA330\)](#)
[HUMAN ANTI IPILIMUMAB \(DRUG/TARGET COMPLEX\) \(HCA331\)](#)

North & South America Tel: +1 800 265 7376
Fax: +1 919 878 3751
Email: antibody_sales_us@bio-rad.com

Worldwide Tel: +44 (0)1865 852 700
Fax: +44 (0)1865 852 739
Email: antibody_sales_uk@bio-rad.com

Europe Tel: +49 (0) 89 8090 95 21
Fax: +49 (0) 89 8090 95 50
Email: antibody_sales_de@bio-rad.com

'M371782:200612'

Printed on 11 Aug 2020

© 2020 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)